Palatin Technologies, Inc. (PTN) Stock

Palatin Technologies, Inc. (PTN) is a Healthcare stock trading at $10.26 (as of 2026-08-20), with a market capitalization of $18.26M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Palatin Technologies, Inc. is a biopharmaceutical company developing receptor-targeted therapeutic candidates for treatment of diseases in the United States. Its pipeline includes Vyleesi for hypoactive sexual desire disorder and multiple peptide programs in areas such as inflammatory bowel disease, ocular inflammation, and cardiovascular conditions.

Understand Palatin Technologies, Inc.: how it makes money

Palatin Technologies develops targeted receptor-specific biopharmaceuticals, and its current monetization is through net product revenue from Vyleesi.

The profit model is driven by whether Vyleesi produces net product revenue, with future growth dependent on pipeline progress from PL8177 and PL9643.

Revenue by segment (latest quarter)
Vyleesi Net Product Revenue$0.0B

Business quality (Weak): Good clarity on the business and product focus, but the latest reported quarter shows 0.0B revenue, so near-term fundamentals depend heavily on whether Vyleesi monetizes and whether pipeline milestones translate into later-stage results.

Bull case

  • Lead product with defined indication: Vyleesi is Palatin's lead product, an MCr agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
  • Promising clinical signal metrics: Clinical Remission Rate is 33.0 percent, and Clinical Response Rate is 78.0 percent.
  • Pipeline has advanced to at least early clinical testing: Oral PL8177 has completed Phase I clinical trial for inflammatory bowel diseases.

Bear case

  • No reported net product revenue in the latest quarter: For the period ending 2026-03-31, net product revenue of Vyleesi is 0.0B and total revenue_b is 0.0B.
  • Operating losses: Operating margin is -40.3 for the period ending 2026-03-31.
  • Pipeline is not yet described beyond Phase I for PL8177: PL8177 has completed Phase I, and PL9643 is described as being in development, which leaves uncertainty around later-stage efficacy, regulatory outcomes, and commercialization timeline.
Valuation — source: SEC EDGAR (first-party)
Price$10.26
Market Cap$18.26M
Price / Book1.72
Price / Sales1.42
FCF Yield-145.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Revenue Growth (YoY)-100.0%
FCF Growth (YoY)-32.4%
Financial Health — source: SEC EDGAR
Altman Z-Score-215.49 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderDriehaus Capital Management LLC ($2.90M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOCarl Spana
Employees30
CountryUS
IPO Date1997-10-15

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Marker Therapeutics, Inc. (MRKR)
  • Biofrontera Inc. (BFRI)
  • Celularity Inc. (CELU)
  • Cyclerion Therapeutics, Inc. (CYCN)
  • Tvardi Therapeutics, Inc. (TVRD)
  • Tempest Therapeutics, Inc. (TPST)
  • Vyome Holdings, Inc. (HIND)
  • KALA BIO, Inc. (KALA)
PTN earnings history · PTN institutional & insider holders · PTN KPIs & operating metrics · PTN financials · PTN investor presentations & press releases · PTN SEC filings · PTN peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.